Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 97

Similar articles for PubMed (Select 23996323)

1.

Subcutaneous herceptin therapy.

O'Donoghue N, Quintyne KI, Woulfe B, Gupta R, O'Reilly S.

J Clin Pharmacol. 2013 Dec;53(12):1341-2. doi: 10.1002/jcph.171. Epub 2013 Sep 21. No abstract available.

PMID:
23996323
2.

Reply to: letter to the editor "subcutaneous herceptin therapy".

Wynne C, Harvey V, Schwabe C, Waaka D, McIntyre C, Bittner B.

J Clin Pharmacol. 2013 Dec;53(12):1343-4. doi: 10.1002/jcph.172. Epub 2013 Sep 21. No abstract available.

PMID:
23996383
3.

Subcutaneous trastuzumab (Herceptin) injection shows promise.

[No authors listed]

Oncology (Williston Park). 2012 Sep;26(9):873. No abstract available.

4.

As treatment options progress, so must we.

Harmer V.

Br J Nurs. 2013 May 23-Jun 12;22(10):S3. No abstract available.

PMID:
23752364
5.

[Is Herceptin(®) (trastuzumab) by subcutaneous a mini revolution? Pharmaco-economic study].

Lieutenant V, Toulza É, Pommier M, Lortal-Canguilhem B.

Bull Cancer. 2015 Mar;102(3):270-6. doi: 10.1016/j.bulcan.2015.01.007. Epub 2015 Feb 25. Review. French.

PMID:
25725921
6.

Can NOAH guide us to improved survival in breast cancer?

Johnston SR.

Lancet Oncol. 2014 May;15(6):550-2. doi: 10.1016/S1470-2045(14)70116-0. Epub 2014 Mar 20. No abstract available.

PMID:
24657002
7.

Is there an ideal way to combine trastuzumab with chemotherapy?

Gonzalez-Angulo AM, Hortobagyi GN.

J Clin Oncol. 2011 Dec 1;29(34):4474-6. doi: 10.1200/JCO.2011.38.3836. Epub 2011 Oct 31. No abstract available.

8.

Targeted therapies: HERA update-1 year is standard.

Hutchinson L.

Nat Rev Clin Oncol. 2013 Oct;10(10):546. doi: 10.1038/nrclinonc.2013.145. Epub 2013 Aug 6. No abstract available.

PMID:
23917526
9.

[Current studies reveal significant survival advantage. Breast cancer therapy with herceptin].

[No authors listed]

Krankenpfl J. 2003;41(10-12):215. German. No abstract available.

PMID:
14746196
10.

PrefHer: finally addressing the preferences of her, too.

Melichar B.

Lancet Oncol. 2013 Sep;14(10):914-5. doi: 10.1016/S1470-2045(13)70389-9. Epub 2013 Aug 19. No abstract available.

PMID:
23965224
11.

The hype over herceptin.

Fitzpatrick J.

Nurs N Z. 2009 Mar;15(2):4-5. No abstract available.

PMID:
19554708
12.

[Combination therapy herceptin+taxotere/Herceptin+navelbine].

Meden H.

Onkologie. 2002 Dec;25 Suppl 5:15-6. German. No abstract available.

PMID:
23573614
13.

Herceptin in elderly patients.

Bighin C, Stevani I, Venturini M.

Tumori. 2002 Jan-Feb;88(1 Suppl 1):S37-8. No abstract available.

PMID:
11989920
14.

[Herceptin-based therapy for breast cancer].

Tokuda Y, Saito Y, Suzuki Y.

Nihon Rinsho. 2006 Mar;64(3):540-5. Review. Japanese.

PMID:
16529047
15.

Monoclonal antibody therapy for breast cancer: herceptin.

Finn RS, Slamon DJ.

Cancer Chemother Biol Response Modif. 2003;21:223-33. Review. No abstract available.

PMID:
15338747
16.

Breast cancer drug warning.

[No authors listed]

Johns Hopkins Med Lett Health After 50. 2012 Dec;24(11):8. No abstract available.

PMID:
23342677
17.

Desensitization to chemotherapeutic agents.

Lieberman P, Castells M.

J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):116-7. doi: 10.1016/j.jaip.2013.08.013. No abstract available.

PMID:
24565784
18.

Weekly paclitaxel plus Herceptin in metastatic breast cancer patients who relapse after stem-cell transplant.

Sporn JR, Bilgrami SA.

Ann Oncol. 1999 Oct;10(10):1259-60. No abstract available.

19.

[Pertuzumab (PERJETA(®) intravenous infusion 420 mg/14 mL): pharmacological properties and clinical development overview].

Myobudani H, Ushiyama N, Ichinose R, Takasuka T.

Nihon Yakurigaku Zasshi. 2014 Feb;143(2):95-102. Review. Japanese. No abstract available.

PMID:
24531903
20.

Ado-trastuzumab emtansine approved for advanced breast cancer.

Traynor K.

Am J Health Syst Pharm. 2013 Apr 1;70(7):562. doi: 10.2146/news130023. No abstract available. Erratum in: Am J Health Syst Pharm. 2013 May 15;70(10):840.

PMID:
23515502
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk